10:48 AM EDT, 05/24/2024 (MT Newswires) -- Apellis Pharmaceuticals ( APLS ) and Sobi said Friday that the one-year data from the phase 2 study of pegcetacoplan showed a rapid reduction in post-transplant kidney disease activity in 12 weeks that was sustained over one year.

The study evaluated the efficacy and safety of pegcetacoplan in patients with post-transplant recurrence of C3 glomerulopathy or primary immune complex membranoproliferative glomerulonephritis, the companies said.

At one year, seven treated patients showed a reduction in C3c staining and zero inflammation, while six patients, including the three IC-MPGN patients, showed zero C3c staining intensity, according to the companies.

The companies said they are evaluating the drug in a wider population of patients with rare kidney diseases in the phase 3 study, with topline results expected later this year.

Apellis shares were up 1.8% in recent trading.

Price: 40.41, Change: +0.73, Percent Change: +1.84